MyMD Pharmaceuticals Enrolls First Individual in Stage 2 Professional Test of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Life Expectancy

MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Company”), a medical stage pharmaceutical company committed to prolonging healthy life expectancy, today announced that the initial person has been enlisted in the Firm’s Stage 2 medical test of lead prospect MYMD-1, an oral immune regulatory authority medicine, as a therapy for delaying aging and expanding healthy lifespan.

The main endpoint for the Stage 2 double-blind, placebo-controlled professional trial is to achieve a decrease in the circulating degrees of (TNF-α), growth death factor receptor I (TNFRI) and IL-6. TNF-α as well as IL-6 are the proteins in the body that create inflammation as well as aid activate the procedure of aging. The second actions of the trial will be the safety, tolerability, and pharmacokinetics in this population of individuals.

” In a Phase 1 medical trial of MYMD-1, we demonstrated the medication’s statistically considerable efficiency in minimizing levels of TNF-α, a principal in triggering pathological aging, in the blood. The FDA has accepted TNF-α decrease as the main endpoint for our Stage 2 research study, which our company believe placements us well for a successful Phase 2 result,” stated Chris Chapman, M.D., President, Director and also Principal Medical Policeman of MyMD. “The initiation of client registration in this study advances our objective to reduce the aging process, stop loss of muscle mass tissue in aging, limit frailty, and also prolong healthy life-span.”

MyMD has mentioned that there are no FDA-approved medicines for dealing with aging disorders and extending healthy lifespan humans, a market anticipated to be at the very least $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are the most prescribed medications by profits, a global market of around $40 billion each year,2 as well as, according to Nature Aging journal,3 a stagnation in maturing that would enhance life expectancy by one year deserves $38 trillion and also by one decade deserves $367 trillion.

Along with aging, MYMD-1’s distinctive action in controling the body immune system and also treating chronic inflammation is being established for the treatment of autoimmune illness, including rheumatoid joint inflammation (RA), several sclerosis (MS), diabetic issues, and also inflammatory bowel disease.

” We mean to begin creating methods for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The rising occurrence of rheumatoid joint inflammation and also other autoimmune and also inflammatory conditions are driving need for TNF inhibitors like MYMD-1, and also our team believe our orally carried out medication with extremely low toxicity would certainly be turbulent to the $60 billion market for RA if authorized by the FDA for this indicator.”

Rheumatoid joint inflammation impacts roughly 40 million people around the world.4.

Concerning MYMD-1.

Originally established for autoimmune illness, MYMD-1’s key function is to slow down the aging procedure, avoid sarcopenia and frailty, as well as extend healthy and balanced life expectancy. Because it can go across the blood-brain obstacle and gain access to the main nerve system (CNS), MYMD-1 is additionally placed to be a possible therapy for brain-related disorders. Its mechanism of activity and efficacy in diseases including several sclerosis (MS) and thyroiditis have been researched through partnerships with several academic organizations. MYMD-1 is also revealing guarantee in pre-clinical studies as a potential treatment for blog post- COVID-19 complications and as an anti-fibrotic as well as anti-proliferation healing.

MYMD-1 has revealed performance in pre-clinical research studies in managing the immune system by doing as a careful prevention of lump necrosis factor-alpha (TNF-α), a chauffeur of chronic inflammation. Unlike various other treatments, MYMD-1 has been shown in these pre-clinical studies to precisely block TNF-α when it ends up being overactivated in autoimmune diseases and cytokine storms, yet not block it from doing its normal job of being an initial -responder to any type of regular sort of moderate infection. MYMD-1’s simplicity of oral application is an additional differentiator compared to presently available TNF-α blockers, all of which need distribution by shot or infusion. No accepted TNF prevention has actually ever before been dosed orally. Furthermore, the medicine is not immunosuppressive and also has not been revealed to trigger the major adverse effects typical with standard therapies that deal with swelling.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical business dedicated to extending healthy life-span, is focused on creating two novel therapeutic systems that treat the reasons for disease as opposed to only dealing with the signs and symptoms. MYMD-1 is a medication platform based on a professional stage tiny particle that controls the body immune system to control TNF-α, which drives persistent swelling, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase long life, and treat autoimmune illness as well as COVID-19- associated depression. The Firm’s 2nd drug platform, Supera-CBD, is being developed to treat persistent pain, addiction as well as epilepsy. Supera-CBD is an unique artificial by-product of cannabidiol (CBD) as well as is being established to deal with and improve upon the rapidly growing CBD market, that includes both FDA approved drugs as well as CBD products not presently controlled as medicines. To find out more, visit www.mymd.com.